440 related articles for article (PubMed ID: 21542122)
1. A randomized trial of intravenous n-acetylcysteine to prevent contrast induced nephropathy in acute coronary syndromes.
Jaffery Z; Verma A; White CJ; Grant AG; Collins TJ; Grise MA; Jenkins JS; McMullan PW; Patel RA; Reilly JP; Thornton SN; Ramee SR
Catheter Cardiovasc Interv; 2012 May; 79(6):921-6. PubMed ID: 21542122
[TBL] [Abstract][Full Text] [Related]
2. Short-term, high-dose Atorvastatin pretreatment to prevent contrast-induced nephropathy in patients with acute coronary syndromes undergoing percutaneous coronary intervention (from the ARMYDA-CIN [atorvastatin for reduction of myocardial damage during angioplasty--contrast-induced nephropathy] trial.
Patti G; Ricottini E; Nusca A; Colonna G; Pasceri V; D'Ambrosio A; Montinaro A; Di Sciascio G
Am J Cardiol; 2011 Jul; 108(1):1-7. PubMed ID: 21529740
[TBL] [Abstract][Full Text] [Related]
3. Intravenous N-acetylcysteine plus high-dose hydration versus high-dose hydration and standard hydration for the prevention of contrast-induced nephropathy: CASIS--a multicenter prospective controlled trial.
Koc F; Ozdemir K; Kaya MG; Dogdu O; Vatankulu MA; Ayhan S; Erkorkmaz U; Sonmez O; Aygul MU; Kalay N; Kayrak M; Karabag T; Alihanoglu Y; Gunebakmaz O
Int J Cardiol; 2012 Mar; 155(3):418-23. PubMed ID: 21106264
[TBL] [Abstract][Full Text] [Related]
4. N-acetylcysteine and/or ascorbic acid versus placebo to prevent contrast-induced nephropathy in patients undergoing elective cardiac catheterization: The NAPCIN trial; A single-center, prospective, randomized trial.
Habib M; Hillis A; Hammad A
Saudi J Kidney Dis Transpl; 2016 Jan; 27(1):55-61. PubMed ID: 26787567
[TBL] [Abstract][Full Text] [Related]
5. Effect of N-acetylcysteine on cystatin C-based renal function after elective coronary angiography (ENABLE Study): a prospective, randomized trial.
Kim BJ; Sung KC; Kim BS; Kang JH; Lee KB; Kim H; Lee MH
Int J Cardiol; 2010 Feb; 138(3):239-45. PubMed ID: 18793808
[TBL] [Abstract][Full Text] [Related]
6. Prevention of contrast-induced acute kidney injury in patients with stable chronic renal disease undergoing elective percutaneous coronary and peripheral interventions: randomized comparison of two preventive strategies.
Hafiz AM; Jan MF; Mori N; Shaikh F; Wallach J; Bajwa T; Allaqaband S
Catheter Cardiovasc Interv; 2012 May; 79(6):929-37. PubMed ID: 21542114
[TBL] [Abstract][Full Text] [Related]
7. Intrarenal application of N-acetylcysteine for the prevention of contrast medium-induced nephropathy in primary angioplasty.
Aslanger E; Uslu B; Akdeniz C; Polat N; Cizgici Y; Oflaz H
Coron Artery Dis; 2012 Jun; 23(4):265-70. PubMed ID: 22343798
[TBL] [Abstract][Full Text] [Related]
8. Acetylcysteine in the prevention of contrast-induced nephropathy after coronary angiography.
Oldemeyer JB; Biddle WP; Wurdeman RL; Mooss AN; Cichowski E; Hilleman DE
Am Heart J; 2003 Dec; 146(6):E23. PubMed ID: 14661012
[TBL] [Abstract][Full Text] [Related]
9. Improved estimation of glomerular filtration rate by serum cystatin C in preventing contrast induced nephropathy by N-acetylcysteine or zinc--preliminary results.
Kimmel M; Butscheid M; Brenner S; Kuhlmann U; Klotz U; Alscher DM
Nephrol Dial Transplant; 2008 Apr; 23(4):1241-5. PubMed ID: 18174269
[TBL] [Abstract][Full Text] [Related]
10. N-acetylcysteine reduces contrast-associated nephropathy but not clinical events during long-term follow-up.
Miner SE; Dzavik V; Nguyen-Ho P; Richardson R; Mitchell J; Atchison D; Seidelin P; Daly P; Ross J; McLaughlin PR; Ing D; Lewycky P; Barolet A; Schwartz L
Am Heart J; 2004 Oct; 148(4):690-5. PubMed ID: 15459602
[TBL] [Abstract][Full Text] [Related]
11. Prevention of contrast-induced nephropathy with single bolus erythropoietin in patients with diabetic kidney disease: A randomized controlled trial.
Shema-Didi L; Kristal B; Eizenberg S; Marzuq N; Sussan M; Feldman-Idov Y; Ofir P; Atar S
Nephrology (Carlton); 2016 Apr; 21(4):295-300. PubMed ID: 26370061
[TBL] [Abstract][Full Text] [Related]
12. A randomized controlled trial of intravenous N-acetylcysteine for the prevention of contrast-induced nephropathy after cardiac catheterization: lack of effect.
Webb JG; Pate GE; Humphries KH; Buller CE; Shalansky S; Al Shamari A; Sutander A; Williams T; Fox RS; Levin A
Am Heart J; 2004 Sep; 148(3):422-9. PubMed ID: 15389228
[TBL] [Abstract][Full Text] [Related]
13. Comparison of combination therapy of high-dose oral N-acetylcysteine and intravenous sodium bicarbonate hydration with individual therapies in the reduction of Contrast-induced Nephropathy during Cardiac Catheterisation and Percutaneous Coronary Intervention (CONTRAST): A multi-centre, randomised, controlled trial.
Chong E; Poh KK; Lu Q; Zhang JJ; Tan N; Hou XM; Ong HY; Azan A; Chen SL; Chen JY; Ali RM; Fang WY; Lau TW; Tan HC
Int J Cardiol; 2015 Dec; 201():237-42. PubMed ID: 26301645
[TBL] [Abstract][Full Text] [Related]
14. Red cell distribution width predicts contrast-induced nephropathy in patients undergoing percutaneous coronary intervention for acute coronary syndrome.
Kurtul A; Yarlioglues M; Murat SN; Demircelik MB; Acikgoz SK; Ergun G; Duran M; Cetin M; Ornek E
Angiology; 2015 May; 66(5):433-40. PubMed ID: 24834929
[TBL] [Abstract][Full Text] [Related]
15. Prevention of contrast-induced nephropathy with N-acetylcysteine or sodium bicarbonate in patients with ST-segment-myocardial infarction: a prospective, randomized, open-labeled trial.
Thayssen P; Lassen JF; Jensen SE; Hansen KN; Hansen HS; Christiansen EH; Junker A; Ravkilde J; Thuesen L; Veien KT; Jensen LO
Circ Cardiovasc Interv; 2014 Apr; 7(2):216-24. PubMed ID: 24714489
[TBL] [Abstract][Full Text] [Related]
16. Prevention of contrast-induced nephropathy in vascular patients undergoing angiography: a randomized controlled trial of intravenous N-acetylcysteine.
Rashid ST; Salman M; Myint F; Baker DM; Agarwal S; Sweny P; Hamilton G
J Vasc Surg; 2004 Dec; 40(6):1136-41. PubMed ID: 15622367
[TBL] [Abstract][Full Text] [Related]
17. Abbreviated dosing of N-acetylcysteine prevents contrast-induced nephropathy after elective and urgent coronary angiography and intervention.
Ochoa A; Pellizzon G; Addala S; Grines C; Isayenko Y; Boura J; Rempinski D; O'Neill W; Kahn J
J Interv Cardiol; 2004 Jun; 17(3):159-65. PubMed ID: 15209578
[TBL] [Abstract][Full Text] [Related]
18. Efficacy of alprostadil in preventing contrast-induced nephropathy in patients undergoing percutaneous coronary intervention: A multicenter prospective randomized controlled trial.
Liang M; Yang S; Fu N; Lu C; Tian F; Xing X; Lin W; Liu J
Catheter Cardiovasc Interv; 2018 Mar; 91(4):742-750. PubMed ID: 29024304
[TBL] [Abstract][Full Text] [Related]
19. N-acetylcysteine does not prevent contrast-induced nephropathy after cardiac catheterization in patients with diabetes mellitus and chronic kidney disease: a randomized clinical trial.
Amini M; Salarifar M; Amirbaigloo A; Masoudkabir F; Esfahani F
Trials; 2009 Jun; 10():45. PubMed ID: 19563648
[TBL] [Abstract][Full Text] [Related]
20. N-acetylcysteine versus AScorbic acid for preventing contrast-Induced nephropathy in patients with renal insufficiency undergoing coronary angiography NASPI study-a prospective randomized controlled trial.
Jo SH; Koo BK; Park JS; Kang HJ; Kim YJ; Kim HL; Chae IH; Choi DJ; Sohn DW; Oh BH; Park YB; Choi YS; Kim HS
Am Heart J; 2009 Mar; 157(3):576-83. PubMed ID: 19249432
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
